跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
AML-3
首页
药物
AML-3
AML-3
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Methods to impair hematologic cancer progenitor cells and compounds related thereto
US 7651678 B2
申请人: UNIV KENTUCKY RES FOUND
优先权: 2001
US
8 件公开
Method for treatment of blood tumor using anti-TIM-3 antibody
US 8647623 B2
申请人: TAKAYANAGI SHINICHIRO
优先权: 2009
US
6 件公开
COMPOSITIONS COMPRISING A DHODH INHIBITOR FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
EP 4048251 A1
申请人: RHIZEN PHARMACEUTICALS AG
优先权: 2019
CN
EP
US
WO
4 件公开
CD70 combination therapy
US 11530271 B2
申请人: ARGENX BV
优先权: 2018
CN
EP
US
4 件公开
Antibodies specific for FLT3 and their uses
US 11421040 B2
申请人: PFIZER
优先权: 2017
CN
US
4 件公开
DOSAGE REGIMEN FOR SAPACITABINE AND DECITABINE IN COMBINATION FOR TREATING ACUTE MYELOID LEUKEMIA
EP 3560501 A1
申请人: CYCLACEL LTD
优先权: 2011
EP
US
3 件公开
Nitrogen-containing heterocyclic compound or salt thereof
US 9145415 B2
申请人: FUJIFILM CORP
优先权: 2012
CN
US
3 件公开
Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereof
US 11203601 B2
申请人: BROAD INST INC
优先权: 2017
CN
US
3 件公开
Human monoclonal antibodies specific for FLT3 and uses thereof
US 11236171 B2
申请人: US HEALTH
优先权: 2017
EP
US
3 件公开
Targeting Pleckstrin-2 for treating cancer
US 12629424 B2
申请人: UNIV NORTHWESTERN
优先权: 2018
US
WO
3 件公开
第 1 / 6 页
上一页
下一页
药物
反馈